Reaction

Bile Duct Stenosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,187 reports · 45 co-occurring drugs

As of the last recalculation, Bile Duct Stenosis appears in 1,187 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is URSOSIOL (PRR 38.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ursosiol	41	38.3	38.4
Ursodiol	41	34.2	34.2
Basiliximab	20	30.3	30.4
Everolimus Tablets	27	28.9	28.9
Durvalumab	30	26.5	26.5
Gemcitabine Hydrochloride	67	23.4	23.4
Gemcitabine	45	20.8	20.8
Tacrolimus	146	18.5	18.5
Tacrolimus Ointment 0.1%	109	16.8	16.8
Tacrolimus Extended-Release Capsules	109	16.8	16.8
Ganciclovir Sodium	10	16.7	16.7
Irinotecan Hydrochloride	12	16.5	16.5
Goserelin	12	15.8	15.8
Ganciclovir	9	15.5	15.5
Erlotinib Hydrochloride	10	14.1	14.1
Fulvestrant	26	14.1	14.1
Mycophenolate Mofetil	99	13.9	13.9
Mycophenolate Mofetil Hydrochloride	99	13.8	13.8
Sitagliptin	52	13.2	13.2
Everolimus	37	13.1	13.1
Pancrelipase	28	13.0	13.0
Paclitaxel	68	12.7	12.7
Letrozole Tablets	33	12.3	12.4
Sirolimus	9	11.8	11.8
Teduglutide	9	11.8	11.8
Sitagliptin And Metformin Hydrochloride	14	11.5	11.5
Lanreotide Acetate	5	11.2	11.2
Atezolizumab	23	10.6	10.6
Ribociclib	17	9.6	9.6
Erlotinib	5	9.1	9.1
Panitumumab	8	9.0	9.0
Ipilimumab	20	8.2	8.3
Bevacizumab	55	8.1	8.1
Lapatinib	7	8.0	8.0
Entecavir	5	7.5	7.5
Vedolizumab	35	7.3	7.3
Paclitaxel (Aibumin-Bound)	33	7.2	7.2
Nivolumab	37	6.9	6.9
Cetuximab	11	6.2	6.2
Vismodegib	3	5.9	5.9
Sofosbuvir	6	5.4	5.4
Encorafenib	3	5.3	5.3
Exenatide	13	4.4	4.4
Lenvatinib	8	4.3	4.3
Ledipasvir And Sofosbuvir	4	3.7	3.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.